Recursion Pharmaceuticals (RXRX) Set to Release Quarterly Earnings on Wednesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is projected to release its Q3 2026 & Study Update results before the market opens on Wednesday, November 4th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.2190) per share and revenue of $14.81 million for the quarter. Parties may visit the company’s upcoming Q3 2026 & Study Update earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same period last year, the firm posted ($0.41) earnings per share. On average, analysts expect Recursion Pharmaceuticals to post ($0.93) EPS for the current fiscal year and ($0.87) EPS for the next fiscal year.

Recursion Pharmaceuticals Trading Up 6.6%

NASDAQ RXRX opened at $4.05 on Wednesday. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $6.25. The company has a 50 day moving average of $3.69 and a 200-day moving average of $3.55. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -3.89 and a beta of 1.04.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Robert Hershberg sold 25,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the sale, the director directly owned 162,156 shares of the company’s stock, valued at $810,780. This represents a 13.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the sale, the director directly owned 6,108,287 shares of the company’s stock, valued at approximately $29,564,109.08. This represents a 0.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 157,408 shares of company stock worth $643,576. 6.65% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

RXRX has been the topic of a number of research analyst reports. Morgan Stanley set a $5.90 price target on Recursion Pharmaceuticals in a research report on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, October 15th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.18.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.